Cameron John Reynolds, President and CEO and Director of VolitionRx Ltd, filed a Form 4 on November 20, 2026, disclosing a purchase of 40,000 shares of common stock on November 19, 2026.

Key Highlights

  • Purchase transaction: Reynolds acquired 40,000 shares of VolitionRx Ltd common stock on November 19, 2026, at a price of $0.1712 per share.
  • Direct ownership after transaction: Reynolds directly holds 185,781 shares of common stock following the reported transaction.
  • Indirect ownership via Concord International: An additional 50,386 shares are held indirectly through Concord International, Inc., of which Reynolds is the majority shareholder and shares voting and dispositive control.
  • Indirect ownership via spouse: A further 1,704 shares are held indirectly by Reynolds's spouse.
  • Reverse stock split adjustment: On April 28, 2026, the issuer effected a one-for-20 reverse stock split; share counts in the filing have been retroactively adjusted to reflect this split.
  • Roles: Reynolds is identified in the filing as both a Director and the President and CEO of VolitionRx Ltd (NASDAQ:VNRX).

Reynolds Open-Market Purchase and Post-Transaction Ownership in VolitionRx

According to the filing, Cameron John Reynolds, serving as President, CEO, and Director of VolitionRx Ltd, reported a purchase (transaction code "P") of 40,000 shares of common stock on November 19, 2026, at $0.1712 per share. The transaction is reported on Table I of the Form 4 as shares acquired directly.

Following the transaction, the filing discloses that Reynolds directly holds 185,781 shares. In addition, 50,386 shares are held indirectly through Concord International, Inc. The filing states that Reynolds is the majority shareholder of Concord International, Inc. and "shares voting and dispositive control over the shares of common stock held by Concord International, Inc." A further 1,704 shares are held indirectly by Reynolds's spouse. All share counts reflect retroactive adjustment for the one-for-20 reverse stock split that the issuer effected on April 28, 2026, as noted in the filing's explanation of responses.

The filing notes that no fractional shares were issued in connection with the reverse split, and that each holder otherwise entitled to a fractional share received one whole share instead. No derivative securities transactions are reported in Table II of this filing. The Form 4 was signed by Cameron John Reynolds and filed on November 20, 2026.

What Was Disclosed

Reynolds filed a Form 4 reporting a November 19, 2026, open-market purchase of 40,000 VolitionRx common shares at $0.1712 each. Post-transaction, he holds 185,781 shares directly, plus 50,386 and 1,704 shares held indirectly through Concord International, Inc. and his spouse, respectively.